Buy me a coffee
Home › FDA recalls › Everolimus tablets 5mg
CLASS III · LowFDA

Endo USA, Inc. recalls Everolimus tablets 5mg

📅 Oct 10, 2025 · 📍 Nationwide
Recalling company
Endo USA, Inc.
Product
Everolimus tablets 5mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-125-91
Reason
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
Classification
Class III – not likely to cause adverse health consequences
Recall date
Oct 10, 2025
Reported
Nov 5, 2025
Distribution
Nationwide within the United States
Status
Ongoing
Quantity
6,655 cartons
Lot / codes
Lot #: 550184901, 550185001, Exp. Date MAR-26; 550189901, 550190001, Exp. Date APR-26 550203901, 550205601, Exp. Date Jul-26
Company location
Malvern, PA
Recall type
Voluntary: Firm initiated
Recall number
D-0139-2026
Agency
U.S. Food and Drug Administration (FDA)

View official FDA notice ↗ Search recall number D-0139-2026 in the FDA Enforcement Report. Also see FDA recall press releases.

If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.